Tag - TRIL

Developments

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

Pfizer (NYSE:PFE) entered into a definitive agreement to acquire Trillium Therapeutics (NASDAQ, TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. ...

August 23, 2021

Markets

HCW cuts Trillium Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Trillium Therapeutics (NASDAQ:TRIL) to “neutral” from “buy” and removed its price target, saying the precipitous fall in the stock price could lead to a cash crunch. Over the last six months...

August 19, 2019

Tag - TRIL

Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies

HCW cuts Trillium Therapeutics to neutral and removes PT

General

More